Literature DB >> 3342750

Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor.

M F Press1, G L Greene.   

Abstract

A series of rat and mouse monoclonal antibodies to the human progesterone receptor (PR) has recently been produced. These antibodies were used for the immunocytochemical identification of PR in several mammalian species including humans. The specificity of the monoclonal antibodies for PR was confirmed by using competition studies with purified PR and by comparison of the immunostained tissues, known from steroid binding assays to be receptor rich, with immunostained tissues known to be receptor-poor. Immunoreactive PR was found in the nuclei of uterine epithelial, stromal, and smooth muscle cells; benign ductal and lobular epithelial cells of the breast; ovarian surface epithelium; ovarian stroma and luteal cells; pulmonary parenchymal cells; and selected pituitary parenchymal cells. A proportion of the following selected human tumors expressed PR: breast carcinomas, endometrial carcinomas, ovarian carcinomas, and meningiomas. PR was localized to the nuclei of all progesterone target tissues even under conditions where the vast majority of the receptor is unoccupied by steroid, suggesting that the unoccupied as well as the steroid-occupied form of PR are predominantly nuclear proteins, as observed previously for estrogen receptor and rabbit PR.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3342750     DOI: 10.1210/endo-122-3-1165

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  34 in total

Review 1.  Progesterone signaling and mammary gland morphogenesis.

Authors:  G Shyamala
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-01       Impact factor: 2.673

Review 2.  Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.

Authors:  R K Hansen; M J Bissell
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

3.  Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor.

Authors:  J G Savory; B Hsu; I R Laquian; W Giffin; T Reich; R J Haché; Y A Lefebvre
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

4.  Downregulation of nuclear progestin receptor (Pgr) and subfertility in double knockouts of progestin receptor membrane component 1 (pgrmc1) and pgrmc2 in zebrafish.

Authors:  Xin-Jun Wu; Yong Zhu
Journal:  Gen Comp Endocrinol       Date:  2019-09-16       Impact factor: 2.822

5.  Immunohistochemical versus biochemical estrogen-receptor and progesterone-receptor analysis: correlation with histological parameters.

Authors:  M Helle; M Helin; J Isola; H Helin
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

6.  Anatomical variation of the oestrogen receptor in normal myometrium.

Authors:  P A Richards; A J Tiltman
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

7.  Immunocytochemical localization of progesterone receptors in endocrine cells of the human pancreas.

Authors:  C Doglioni; M Gambacorta; G Zamboni; G Coggi; G Viale
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

8.  Progesterone Receptor Serves the Ovary as a Trigger of Ovulation and a Terminator of Inflammation.

Authors:  Chan Jin Park; Po-Ching Lin; Sherry Zhou; Radwa Barakat; Shah Tauseef Bashir; Jeong Moon Choi; Joseph A Cacioppo; Oliver R Oakley; Diane M Duffy; John P Lydon; CheMyong J Ko
Journal:  Cell Rep       Date:  2020-04-14       Impact factor: 9.423

9.  Progesterone receptors in routinely paraffin-embedded primary breast carcinomas and lymph node metastases.

Authors:  E Müller-Holzner; A G Zeimet; G Daxenbichler; C Marth; L C Müller; O Dapunt
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  Estrogen receptors, progesterone receptors, and cell proliferation in human breast cancer.

Authors:  M A Fanelli; L M Vargas-Roig; F E Gago; O Tello; R Lucero De Angelis; D R Ciocca
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.